IL21 and melanoma: Thus, treatment with IL-21 + low-dose IL-2 after the adoptive transfer of pmel Tg CD8+ T cells into mice with established B16 melanoma tumors (pmel Tg/B16 model) might yield anti-tumor effects comparable to or greater than those observed with IL-21+IL-15.